Artificial Intelligence: A Promising New Tool for Treating Liver Cancer
“We look to the clinicians to give us the appropriate clinical questions, then we try to develop algorithms that would address those issues.” Yale biomedical engineer Lawrence Staib, PhD, on using artificial intelligence to help with liver cancer treatment.
Taking artificial intelligence out of the black box: An “interpretable” deep learning system for liver tumour diagnosis
Convolutional neural networks (CNN) have demonstrated the potential to become effective and accurate decision support tools for radiologists. A major barrier to clinical translation, however, is that the majority of such algorithms currently function like a “black box”.
Artificial intelligence will cause “paradigm shift” in IR practice
Clinicians are calling for increased collaboration between computer scientists, biomedical engineers and interventional radiologists as machine learning is posited to play a more prominent role in interventional radiology (IR) procedures, from informing the initial diagnosis, through to patient selection and intraprocedural guidance. In a recent primer published in The Journal of Vascular and Interventional Radiology (JVIR), Brian Letzen, Clinton Wang and Julius Chapiro, all of the Yale School of Medicine, New Haven, USA, outline the clinical applications of machine learning for IRs, and visualise a future where artificial intelligence (AI) enables the elevation of the discipline to become, in Chapiro’s words, “the epitome of personalised medicine”.
AI in Tumor Diagnostics, Treatment and Follow-up
AI in Tumor Diagnostics, Treatment and Followup Play Mute Current Time 0:27 / Duration 8:01 Non-Fullscreen TRENDING NOW The Debate Over Gadolinium MRI Contrast ToxicityMost Popular Radiology Topics of 2017FDA Clears Siemens Healthineers' Multix Impact Digital X-ray System Julius Chapiro, M.D., research faculty member and an interventional radiology resident at Yale University, describes how artificial intelligence (AI) can be used to revolutionize cancer diagnosis and treatment at the 2018 Radiological Society of North America (RSNA) annual meeting.
Beyond the black box? AI algorithm explains decisions
Yale University researchers have developed an artificial intelligence (AI) algorithm for classifying liver lesions on MRI scans that explains the reason for its decisions. The algorithm could address concerns about the "black box" nature of AI, according to research presented at last week's RSNA 2018 meeting.
Live from RSNA 2017: Julius Chapiro on multi-modality and 3D imaging technologies
Julius Chapiro, Research Scientist, Department of Radiology and Biomedical Imaging, Yale University School of Medicine shares how multi-modality and 3-D imaging technologies continue to exponentially define and benefit the future of cancer care.
WEBINAR: Multi-Modality 3-D Quantitative Imaging in Cancer Care: Clinical Value and Future Perspectives
The CME webinar "Multi-Modality 3D Quantitative Imaging in Cancer Care: Clinical Value and Future Perspectives" will focus on the role of image analysis and artificial intelligence for image-guided, minimally invasive cancer therapies, introduce the audience to the mechanisms and principles of image analysis and outline the growing role of machine learning for the therapeutic algorithm and decision making processes in interventional oncology.
Lipiodol—an effective imaging biomarker for chemoembolization of hepatocellular carcinoma
Hepatocellular carcinoma is the second most common cause of cancer-related deaths worldwide and its incidence is continuing to grow at an alarming rate in Europe and the USA. The clinical management of patients with this disease has greatly evolved over the course of the last three decades. The progress in the field has been mainly driven by innovation in image guidance technology and drug delivery platforms, resulting in substantially improved clinical outcomes. These developments have allowed interventional oncologists to become the primary liaison for patients seeking therapy.
Hacking the future of health at Yale
The Yale Healthcare Hackathon event (#YaleHackHealth) blended passion, creativity and the belief that each one of us can improve the patient experience with new ideas. One believer is Philips Healthcare. The flagship sponsor of the event, Philips shared a passion for patient and provider empowerment throughout the weekend. The event was presented by the Yale Center for Biomedical Innovation and Technology (CBIT) and the Yale School of Medicine Department of Radiology and Biomedical Imaging. The 2017 Yale Healthcare Hackathon was co-organized by Dr. Ayesha Khalid (Yale CBIT Clinical Director) and Dr. Jeffrey Weinreb (Yale School of Medicine, Department of Radiology and Biomedical Imaging). Together, they produced a fantastic event supported by mentors, the Yale radiology team, and the leadership and planning team.
Enabling more impactful radiology solutions for cancer care through co-creation: A model for developing new healthcare tools
There is a lot of talk in the healthcare industry right now about the concept of “co-creation.” This is the idea that health tech suppliers work in close partnership with clinicians, clinical researchers, healthcare administrators, etc. to develop new tools for the healthcare sector. As a clinician myself, I think co-creation is – in principle – an excellent idea. It allows the industry to address challenges that neither tech suppliers nor healthcare providers could tackle on their own. A discussion with Dr. Julius Chapiro.
Philips teams up with leading innovators in interventional oncology
Royal Philips (NYSE: PHG, AEX: PHIA) today announced that as part of the existing Master Research Agreement with Yale School of Medicine, it has entered into a new research program led by Prof. Jeff Geschwind, chair of Radiology and Biomedical Imaging at Yale School of Medicine, to innovate in interventional oncology. Philips will collaborate with Prof. Geschwind and his team on a multi-year cancer research program to explore new concepts in image-guided therapies, as well as diagnostic imaging and informatics. The research program also involves further research groups at Yale School of Medicine.
Dr. Julius Chapiro Is Getting It All at WCIO 2016
Each year, the WCIO programming committee works to provide attendees with a premiere educational event by inviting trusted and experience faculty from all over the world to lend their expertise in the field of interventional oncology. Julius Chapiro, MD, co-director of the Interventional Oncology Research Lab at Charite` University Hospital, will be joining WCIO again this year as an abstract reviewer. IO Insights recently spoke with Dr. Chapiro to discuss the value of interventional oncology, what drew him to the event, and what he thinks key takeaways will be from WCIO 2016.
TACE Advancements Benefit Patients Battling Liver Cancer
Advancements in transarterial chemoembolization (TACE) are improving the odds for patients with a common type of liver cancer, according to researchers who have been studying the procedure for more than a decade. In the interventional procedure, a catheter is threaded under imaging guidance to the artery or arteries in the liver that supply a tumor with blood. After having ensured that the catheter is in good position, chemoembolytic agents are released to destroy the tumor and partially cut off its blood supply. Developed in Japan in the 1980s, TACE quickly produced benefits for patients with intermediate-stage hepatocellular carcinoma (HCC) that was too advanced for surgery.
Philips advances diagnosis and treatment of cancer with launch of IntelliSpace Portal 8.0 featuring new digital radiology capabilities
Strengthening its leadership in connected healthcare informatics, Royal Philips (NYSE: PHG, AEX: PHIA) today announced IntelliSpace Portal 8.0, the latest edition of its advanced data sharing, analytics and visualization platform that helps radiologists detect, diagnose and follow-up on treatment of diseases. Introduced at the 2015 Radiological Society of North America Annual Meeting (RSNA) in Chicago, IL, IntelliSpace Portal 8.0 helps address the changing demands in radiology that result from an increasing prevalence of cancer and its economic toll. It delivers new applications – like fast 3-D quantitative renderings of tumors – in a fully integrated oncology suite to improve diagnostic confidence and patient care.
Trial shows new imaging system may cut X-ray exposure for liver cancer patients
Researchers report that their test of an interventional X-ray guidance device approved by the US Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy for liver cancer.